Skip to main content

Advertisement

SpringerLink
Log in

Androgens and Therapeutic Aspects of Antiandrogens in Women

  • Review Article
  • Published:
The Journal of the Society for Gynecologic Investigation: JSGI Aims and scope Submit manuscript

Abstract

Objectives

We reviewed the mechanisms of androgen actions and the established and experimental uses of antiandrogens in women.

Methods

Relevant studies were identified through a computerized bibliographic search (MEDLINE) and through manual review of bibliographies in relevant publications.

Results

Androgens exert major effects on the junctions of gonads, sex organs, and various “nonproductive” organs and systems, including muscles, liver, skin, nervous system, and the immune system. Most, but not all, of the actions of androgens may be explained by their binding with specific androgen receptors. Antiandrogens prevent androgens from expressing their activity at target cells. They act primarily by binding to androgen receptors and thus preventing activation of receptors by androgens. Steroidal antiandrogens may also exert a wide range of other hormonal and antihormonal effects by interacting with receptors for progesterone, glucocorticoids, and min-eralocorticoids. Furthermore, some antiandrogens may decrease the production of androgens by acting at the hypothalamic-pituitary unit and modifying the release of LH, or by directly inhibiting individual enzymes involved in steroidogenesis. Antiandrogens are widely used in the treatment of women with various hyperandrogenic conditions, including polycystic ovary syndrome, idiopathic hirsutism, acne, seborrhea, and hair loss.

Conclusions

Antiandrogens provide a logical and clinically effective pharmacotherapy of hyperandrogenic disorders. However, both steroidal and nonsteroidal antiandrogens may cause significant side effects, largely because of their interactions not only with androgen receptors, but also with other receptors and various enzymatic activities. Difficulties in designing the optimal antiandrogen largely result from the complexities of androgen metabolism and action in various tissues.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Dorfman RI. Biological activity of antiandrogens. Br J Dermatol 1970;82(suppl 6):3.

    Article  Google Scholar 

  2. Witt BR, Thorneycroft IH. Reproductive steroid hormones: Generation, degradation, reception, and action. Clin Obstet Gynedol 1990;33:563.

    Article  CAS  Google Scholar 

  3. Cunningham GR, Tindall DJ, Lobl TJ, Campbell JA. Steroid structural requirements for high affinity binding to human sex steroid binding protein (SBP). Steroids 1981;38:243.

    Article  CAS  PubMed  Google Scholar 

  4. Hryb DJ, Khan MS, Rosner W. Testosterone-estradiol binding globulin binds to human prostatic cell membranes. Biochem Biophys Res Commun 1985;128:432.

    Article  CAS  PubMed  Google Scholar 

  5. Strelchyonok OA, Avvakumov GV, Survillo LI. A recognition system for sex hormone binding globulin-oestradiol complex in human decidual endometrium plasma membranes. Biochim Biophys Acta 1983;802:459.

    Article  Google Scholar 

  6. Mauvais-Jarvis P, Charransol G, Bobas-Masson F. Simultaneous determination of urinary androstanediol and testosterone as an evaluation of human androgenicity. J Clin Endocrinol Metab 1973;36:452.

    Article  CAS  PubMed  Google Scholar 

  7. Lobo RA, Goebelsmann U, Horton R. Evidence for the importance of peripheral tissue events in the development of hirsutism in polycystic ovary svndrome. J Clin Endocrinol Metab 1983;57:393.

    Article  CAS  PubMed  Google Scholar 

  8. Horton R, Hawks D, Lobo R. 3a, 17P-Androstanediol glucuronide in plasma. J Clin Invest 1982;69:1203.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Giagulli VA, Giorgino R, Vermeulen A. Is plasma 5 al-pha-androstane 3 alpha, 17 beta-diol glucuronide a biochemical marker of hirsutism in women? J Steroid Biochem Mol Biol 1991;39:55.

    Article  CAS  PubMed  Google Scholar 

  10. Giagulli VA, Giorgino RT, Vermeulen A. Origin and significance of plasma androsterone glucuronide levels: A parameter of adrenal androgen secretion and hepatic 5 alpha-reductase activity. J Clin Endocrinol Metab 1993;76:918.

    CAS  PubMed  Google Scholar 

  11. Rittmaster RS, Zwicker H, Thompson DL, Konok G, Norman RW. Androstanediol glucuronide production in human liver, prostate, and skin. Evidence for the importance of the liver in 5 alpha-reduced androgen metabolism. J Clin Endocrinol Metab 1993;76:977.

    CAS  PubMed  Google Scholar 

  12. Pang S, MacGillivary M, Wang M, et al. 3a-Andro-stanediol glucuronide in virilizing congenital adrenal hyperplasia: A useful serum metabolic marker of integrated adrenal androgen secretion. Clin Endocrinol Metab 1991;73:166.

    Article  CAS  Google Scholar 

  13. Reiner B, Donohoue PA, Migeon CJ, Berkovitz GD. Serum 3a-androstanediol glucuronide measurements in sexually mature women with congenital adrenal hyperplasia during therapy. J Clin Endocrinol Metab 1989;69:105.

    Article  CAS  PubMed  Google Scholar 

  14. Giagulli VA, Verdonck L, Giorgino R, Vermeulen A. Precursors of plasma androstanediol- and androgen- glucuronides in women. J Steroid Biochem 1989;33:935.

    Article  CAS  PubMed  Google Scholar 

  15. Rittmaster RS. Androgen conjugates: Physiology and clinical significance. Endocr Rev 1993;14:121.

    Article  CAS  PubMed  Google Scholar 

  16. Lobo RA, Shoupe D, Serafini P, Brinton D, Horton R. The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women. Fertil Steril 1985;43:200.

    Article  CAS  PubMed  Google Scholar 

  17. Carmina E, Lobo RA. Peripheral androgen blockade versus glandular androgen suppression in the treatment of hirsutism. Obstet Gynecol 1991;78:845.

    CAS  PubMed  Google Scholar 

  18. Brown TR, Greene FE, Bardin CW. Androgen receptor dependent and independent activities of testosterone on hepatic microsomal drug metabolism. Endocrinology 1976;99:1353.

    Article  CAS  PubMed  Google Scholar 

  19. Winneker RC, Wagner MM, Shaw CJ, Snyder BW. An-tiandrogens do not reverse androgen-induced inhibition of sex hormone-binding globulin levels in adult female rhesus monkeys. Endocrinology 1989;125:715.

    Article  CAS  PubMed  Google Scholar 

  20. Tilley WD, Marcelli M, McPhaul MJ. Recent studies of the androgen receptor: New insights into old questions. Mol Cell Endocrinol 1990;68:C7.

    Article  CAS  PubMed  Google Scholar 

  21. Wilson JD, Gloyna RE. The intranuclear metabolism of testosterone in the accessory organs of reproduction. Recent Prog Horm Res 1970;26:309.

    CAS  PubMed  Google Scholar 

  22. Silva PD, Gentzschein EEK, Lobo RA. Androstenedione may be a more important precursor of tissue dihydrotes-tosterone than testosterone in women. Fertil Steril 1987;48:419.

    Article  CAS  PubMed  Google Scholar 

  23. Wilson EM, Simental JA, French FS, Sar M. Molecular analysis of the androgen receptor. Ann N Y Acad Sci 1991;637:56.

    Article  CAS  PubMed  Google Scholar 

  24. Imperato-McGinley J, Gauter T, Petersen RE. Steroid 5a-reductase deficiency in man: An inherited form of male pseudohermaphroditism. Science 1974;186:1213.

    Article  CAS  PubMed  Google Scholar 

  25. Wilson JD, George FW, Griffin JE. The hormonal control of sexual development. Science 1981;211:1278.

    Article  CAS  PubMed  Google Scholar 

  26. Janne OA, Shan LX. Structure and function of the androgen receptor. Ann N Y Acad Sci 1991;626:81.

    Article  CAS  PubMed  Google Scholar 

  27. Janne OA, Palvimo JJ, Kallio P, Mehto M. Androgen receptor and mechanism of androgen action. Ann Med 1993;25:83.

    Article  CAS  PubMed  Google Scholar 

  28. Sheridan PJ. Can a single androgen receptor fill the bill? Mol Cell Endocrinol 1991;76:C39.

    Article  CAS  PubMed  Google Scholar 

  29. Andersson S, Berman DM, Jenkins EP, Russell DW. Deletion of steroid 5 alpha-reductase 2 gene in male pseudohermaphroditism. Nature 1991;354:159.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Jenkins EP, Anderson S, Imperato-McGinley J, Wilson JD, Russell DW. Genetic and pharmacological evidence for more than one human steroid 5a-reductase. J Clin Invest 1992;89:293.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Labrie F, Sugimoto Y, Luu-The V, et al. Structure of human type II 5 alpha-reductase gene. Endocrinology 1992;131:1571.

    Article  CAS  PubMed  Google Scholar 

  32. Thigpen AE, Davis DL, Milatovich A, et al. Molecular genetics of steroid 5 alpha-reductase 2 deficiency. J Clin Invest 1992;90:799.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Chang C, Kokontis J, Liao S. Structural analysis of complementary DNA and amino acid sequences of human and rat androgen receptors. Proc Natl Acad Sci USA 1988;85:7211.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Lubahn DB, Joseph DR, Sar M, et al. The human androgen receptor: Complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in prostate. Mol Endocrinol 1988;2:1265.

    Article  CAS  PubMed  Google Scholar 

  35. Carson-Jurica MA, Schrader WT, O’Malley BW. Steroid receptor family: Structure and function. Endocr Rev 1990;11:201.

    Article  CAS  PubMed  Google Scholar 

  36. Chang C, Kokontis J, Liao S. Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 1988;240:324.

    Article  CAS  PubMed  Google Scholar 

  37. George FW, Wilson JD. The regulation of androgen and estrogen formation in fetal gonads. Ann Biol Anim Bio-chim Biophys 1979;19:1297.

    Article  CAS  Google Scholar 

  38. Jost A. Problems of fetal endocrinology: The gonadal and hypophyseal hormones. Recent Prog Horm Res 1953;8:379–89.

    Google Scholar 

  39. Jost A. Embryonic sexual differentiation (morphology, physiology, abnormalities). In: Jones H, Scott WW, eds. Hermaphroditism, genital anomalies, and related endocrine disorders. Baltimore; Williams & Wilkins, 1971:16.

    Google Scholar 

  40. Siiteri PK, Wilson JD. Testosterone formation and metabolism during male sexual differentiation in the human embryo. J Clin Endocrinol Metab 1974;38:113.

    Article  CAS  PubMed  Google Scholar 

  41. Wilson JD, Siiteri PK. Developmental pattern of testosterone synthesis in the fetal gonad of the rabbit. Endocrinology 1973-92:1182.

    Article  CAS  PubMed  Google Scholar 

  42. Grumbach MM, Ducharme JR. The effects of androgen on fetal sexual development: Androgen-induced female pseudohermaphroditism. Fertil Steril 1960;11:157.

    Article  CAS  PubMed  Google Scholar 

  43. Barbieri RL, Ryan KJ. Hyperandrogenism, insulin resistance, and acanthosis nigricans syndrome: A common endocrinopathy with distinct pathophysiologic features. Am J Obstet Gynecol 1983;147:90.

    Article  CAS  PubMed  Google Scholar 

  44. Dunaif A, Graf M, Mandeli J, Laumas V, Dobrjansky A. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab 1987;65:499.

    Article  CAS  PubMed  Google Scholar 

  45. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165.

    Article  CAS  PubMed  Google Scholar 

  46. Dunaif A, Green G, Futterweit W, Dobrjansky A. Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1990;70:699.

    Article  CAS  PubMed  Google Scholar 

  47. Diamanti-Kandrakis E, Mitrakou A, Hennes MMI, et al. Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome. Metabolism 1995;44:525–31.

    Article  Google Scholar 

  48. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994;43:647.

    Article  CAS  PubMed  Google Scholar 

  49. Prelevic GM, Wurzburger MI, Balint-Peric L, et al. Effects of the somatostatin analogue, octreotide, in polycystic ovary syndrome. Metabolism 1992;41:76.

    Article  CAS  PubMed  Google Scholar 

  50. Prelevic GM, Wurzburger MI, Balint-Peric L, Nesic JS. Inhibitory effect of sandostatin on secretion of luteinising hormone and ovarian steroids in polycystic ovary syndrome. Lancet 1990;336:900.

    Article  CAS  PubMed  Google Scholar 

  51. Michel G, Baulieu EE. Androgen receptor in rat skeletal muscle: Characterization and physiological variations. Endocrinology 1980;107:2088.

    Article  CAS  PubMed  Google Scholar 

  52. Bartsch W, Krieg M, Voight KD. Quantification of endogenous testosterone, 5α-dihydrotestosterone, and 5α-androstane-3α, 17(β-diol in subcellular fractions of the prostate, bulbocavernosus/levator ani muscle, skeletal muscle and heart muscle of the rat. J Steroid Biochem 1980;13:259.

    Article  CAS  PubMed  Google Scholar 

  53. McGill HC, Sheridan PJ. Nuclear uptake of sex steroid hormones in the cardiovascular system of the baboon. Circ Res 1981;48:238.

    Article  CAS  PubMed  Google Scholar 

  54. Stenstad P, Eik NK. Androgen metabolism in rat skeletal muscle in vitro. Biochim Biophys Acta 1981;663:169.

    Article  CAS  PubMed  Google Scholar 

  55. Bergamini E, Bomara G, Pellegrino C. The effect of testosterone on glycogen metabolism in rat levator ani muscle. Biochim Biophys Acta 1969;177:220.

    Article  CAS  PubMed  Google Scholar 

  56. Bergamini E. Different mechanisms in testosterone action in glycogen metabolism in rat perineal and skeletal muscles. Endocrinology 1975,96:77.

    Article  CAS  PubMed  Google Scholar 

  57. Krotkiewski M, Kral JG, Karlsson J. Effects of castration and testosterone substitution on body composition and muscle metabolism in rats. Acta Physiol Scand 1980;109:233.

    Article  CAS  PubMed  Google Scholar 

  58. Boissonneault G, Chapdelaine P, Tremblay RR. Actin and creatine kinase mRNAs in rat levator ani and vastus muscles as a function of androgen status. J Appl Physiol 1990;68:1548.

    Article  CAS  PubMed  Google Scholar 

  59. Scow RO, Hagan SN. Effects of testosterone propionate and growth hormone on growth and chemical composition of muscle and other tissues in hypophysectomized male rats. Endocrinology 1965;77:852.

    Article  CAS  PubMed  Google Scholar 

  60. Garcia VV, Sanchez M, Gutierrez M, Cantabrana B, Hidalgo A. Effects of steroidal and nonsteroidal antiandrogens on the left atrium of the rat in vitro. Gen Pharmacol 1991;22:1081.

    Article  Google Scholar 

  61. Garcia VV, Gutierrez M, Cantabrana B, Hidalgo A. Effects of androgens and antiandrogens on the inotropism induced by ouabain and isoproterenol on the left atrium of the rat in vitro. Gen Pharmacol 1992;23:897.

    Article  Google Scholar 

  62. Wild RA, Applebaum BD, Demers LM, et al. Lipoprotein lipids in women with androgen excess: Independent associations with increased insulin and androgen. Clin Chem 1990;36:283.

    Article  CAS  PubMed  Google Scholar 

  63. Mahabeer S, Naidoo C, Norman RJ, Jialal I, Reddi K, Joubert SM. Metabolic profiles and lipoprotein lipid concentrations in nonobese and obese patients with polycystic ovarian disease. Horm Metab Res 1990;22:537.

    Article  CAS  PubMed  Google Scholar 

  64. Dahlgren E, Janson PO, Johansson S, Lapidus L, Oden A. Polycystic ovary syndrome and risk for myocardial infarction. Acta Obstet Gynecol Scand 1992;71:599.

    Article  CAS  PubMed  Google Scholar 

  65. Xu X, de Pergola G, Bjorntrop P. The effects of androgens on the regulation of lipolysis in adipose precursor cells. Endocrinology 1990;126:1229.

    Article  CAS  PubMed  Google Scholar 

  66. Diamanti E, Kaklas N, Spina J, Georgiadou E, Rangou D, Chlouverakis C. The effect of a pure antiandrogen receptor blocker on lipid metabolism in PCO (abstract 1354). 75th Annual Endocrine Society 1993.

    Google Scholar 

  67. Prelevic GM, Wurzburger MI, Trpkovic D, Balint-Peric L. Effects of a low-dose estrogen-antiandrogen combination (Diane-35) on lipid and carbohydrate metabolism in patients with polycystic ovary syndrome. Gynecol Endocrinol 1990;4:157.

    Article  CAS  PubMed  Google Scholar 

  68. Kaiser E, Gruner S. [Long-term studies with an antiandrogen/estrogen combination preparation of its effectiveness, liver tolerance and lipid metabolism in females]. Geburtshilfe Frauenheilkd 1991;51:298.

    Article  CAS  PubMed  Google Scholar 

  69. Landon J, Wynn V, Samols E. The effect of anabolic steroids on blood sugar and plasma insulin levels in man. Metabolism 1963;12:924.

    CAS  PubMed  Google Scholar 

  70. Woodard TL, Burghen GA, Kitabchi AE, Wilimas JA. Glucose intolerance and insulin resistance in aplastic anemia treated with oxymetholone. J Clin Endocrinol Metab 1981;53:905.

    Article  CAS  PubMed  Google Scholar 

  71. Shoupe D, Kumar DD, Lobo RA. Insulin resistance in polycystic ovary syndrome. Am J Obstet Gynecol 1983;147:588.

    Article  CAS  PubMed  Google Scholar 

  72. Seifer DB, Freedman LN, Cavender JR, Baker RA. Insulin-dependent diabetes mellitus associated with danazol. Am J Obstet Gynecol 1990;162:474.

    Article  CAS  PubMed  Google Scholar 

  73. Corenblum B, Baylis BW. Medical therapy for the syndrome of familial virilization, insulin resistance, and acanthosis nigricans. Fertil Steril 1990;53:421.

    Article  CAS  PubMed  Google Scholar 

  74. Herbert CM III, Hill GA, Diamond MP. The use of the intravenous glucose tolerance test to evaluate nonobese hyperandrogenic women. Fertil Steril 1990;53:647.

    Article  PubMed  Google Scholar 

  75. Holmang A, Larsson B-M, Brzezinska Z, Bjorntorp P. Effects of short-term testosterone exposure on insulin sensitivity of muscles in female rats. Am J Physiol 1992;262:E851.

    CAS  PubMed  Google Scholar 

  76. Speiser PW, Serrat J, New MI, Gertner JM. Insulin insen-sitivity in adrenal hyperplasia due to nonclassical steroid 21-hydroxylase deficiency. J Clin Endocrinol Metab 1992;75:1421.

    CAS  PubMed  Google Scholar 

  77. Friedl KE, Jones RE, Hannan CJ, Plymate SR. The administration of pharmacological doses of testosterone or 19-nortestosterone to normal men is not associated with increased insulin secretion or impaired glucose tolerance. J Clin Endocrinol Metab 1989;68:971.

    Article  CAS  PubMed  Google Scholar 

  78. Naftolin F, MacLusky N. Aromatization hypothesis revisited. In: Serio M, ed. Sexual differentiation: Basic and clinical aspects. New York: Raven Press, 1984:79.

    Google Scholar 

  79. Bonsall RW, Rees HD, Michael RP. The distribution, nuclear uptake and metabolism of [3H]dihydrotestosterone in the brain, pituitary gland and genital tract of the male rhesus monkey. J Steroid Biochem 1985;23:389.

    Article  CAS  PubMed  Google Scholar 

  80. Clancy AN, Bonsall RW, Michael RP. Immunohisto-chemical labeling of androgen receptors in the brain of rat and monkey. Life Sci 1992;50:409.

    Article  CAS  PubMed  Google Scholar 

  81. Michael RP, Bonsall RW, Rees HD. The nuclear accumulation of [3H]testosterone and [3H]estradiol in the brain of the female primate: Evidence for the aromatization hypothesis. Endocrinology 1986;118:1935.

    Article  CAS  PubMed  Google Scholar 

  82. Gorski RA, Gordon JR, Shryne JE, Southam AM. Evidence for amorphological sex difference within the medical preoptic area of the rat brain. Brain Res 1978;148:333.

    Article  CAS  PubMed  Google Scholar 

  83. Holloway RL, Lacoste MC. Sexual dimorphism in the human corpus callosum: An extension and replication study. Hum Neurobiol 1986;5:87.

    CAS  PubMed  Google Scholar 

  84. Allen LS, Gorski RA. Sexual dimorphism of the human massa intermedia. Soc Neurosci Abstr 1987;13:46.

    Google Scholar 

  85. Raum WJ, Marcano M, Swerdloff RS. Nuclear accumulation of estradiol derived from aromatization of testosterone is inhibited by hypothalamic beta receptor stimulation in the neonatal female rat. Biol Reprod 1984;30:388.

    Article  CAS  PubMed  Google Scholar 

  86. Gorski RA. Sexual dimorphisms of the brain. J Anim Sci 1985;3:38.

    Article  Google Scholar 

  87. Marynick SP, Loriaux DL, Sherins RJ, Pita JCJ, Lipsett MB. Evidence that testosterone can suppress pituitary gonadotropin secretion independently of peripheral aromatization. J Clin Endocrinol Metab 1979;49:396.

    Article  CAS  PubMed  Google Scholar 

  88. Swerdloff RS, Walsh PC, Odell WD. Control of LH and FSH secretion in the male: Evidence that aromatization of androgens to estradiol is not required for inhibition of gonadotropin secretion. Steroids 1972;20:13.

    Article  CAS  PubMed  Google Scholar 

  89. Debeljuk L, Vilchez-Martinez A, Arimura A, Schally AV. Effect of gonadal steroids on the response to LH-RH in intact and castrated male rats. Endocrinology 1974;94:1519.

    Article  CAS  PubMed  Google Scholar 

  90. Liang T, Brady EJ, Cheung A, Saperstein R. Inhibition of luteinizing hormone (LH)-releasing hormone-induced secretion of LH in rat anterior pituitary ceil culture by testosterone without conversion to 5α-dihydrotestosterone. Endocrinology 1984;115:2311.

    Article  CAS  PubMed  Google Scholar 

  91. Prahalada S, Majka JA, Soper KA, et al. Leydig cell hyperplasia and adenomas in mice treated with finasteride, a 5 alpha-reductase inhibitor: A possible mechanism. Fundam Appl Toxicol 1994;22:211.

    Article  CAS  PubMed  Google Scholar 

  92. Fruzzetti F, de Lorenzo D, Parrini D, Ricci C. Effects of finasteride, a 5 alpha-reductase inhibitor, on circulating androgens and gonadotropin secretion in hirsute women. J Clin Endocrinol Metab 1994;79:831.

    CAS  PubMed  Google Scholar 

  93. Sherins RJ, Loriaux L. Studies on the role of sex steroids in the feedback control of FSH concentration in men. J Clin Endocrinol Metab 1973;36:886.

    Article  CAS  PubMed  Google Scholar 

  94. Naftolin F, Judd HL, Yen SSC. Pulsatile patterns of gonadotropins and testosterone in man: The effect of clomiphene with and without testosterone. J Clin Endocrinol Metab 1973;36:285.

    Article  CAS  PubMed  Google Scholar 

  95. Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994;331:1056.

    Article  CAS  PubMed  Google Scholar 

  96. Serafini P, Silva PD, Paulson RJ, Elkind-Hirsch K, Hernandez M, Lobo RA. Acute modulation of the hypothalamic-pituitary axis by intravenous testosterone in normal women. Am J Obstet Gynecol 1986;155:1288.

    Article  CAS  PubMed  Google Scholar 

  97. Dunaiff A. Do androgens directly regulate gonadotropin secretion in the polycystic ovary syndrome? J Clin Endocrinol Metab 1986;1986:215.

    Google Scholar 

  98. Levin MC, Peterson AC. Emergence and characteristics of sex differences in spatial ability: A metanalysis. Child Dev 1985;56:1479.

    Article  Google Scholar 

  99. Hines M, Green R. Human hormonal and neural correlated of sex-typed behaviors. Rev Psychiatr 1991;10:536.

    Google Scholar 

  100. Money J, Schwartz M, Lewis V. Adult erotosexual status and fetal hormonal masculinization and demasculinization: 46XX congenital virilizing adrenal hyperplasia and 46XY androgen-insensitivity syndrome compared. Psychoneu-roendocrinology 1984;9:405.

    Article  CAS  Google Scholar 

  101. Jost F. [Treatment and resocialization of sexual delinquents by anti-androgen and psychotherapy]. Schweiz Arch Neurol Neurochir Psychiatr 1979;124:243.

    CAS  PubMed  Google Scholar 

  102. Bancroft J, Sanders D, Davidson D, Warner P. Mood, sexuality, hormones, and the menstrual cycle. III. Sexuality and the role of androgens. Psychosom Med 1983;45:509.

    Article  CAS  PubMed  Google Scholar 

  103. Persky H, Dreisbach L, Miller WR, et al. The relation of plasma androgen levels to sexual behaviors and attitudes of women. Psychosom Med 1982;44:305.

    Article  CAS  PubMed  Google Scholar 

  104. Morris NM, Udry JR, Khan-Dawood F, Dawood MY. Marital sex frequency and midcycle female testosterone. Arch Sex Behav 1987;16:27.

    Article  CAS  PubMed  Google Scholar 

  105. Sherwin BB, Gelfand MM. The role of androgen in the maintenance of sexual functioning in oophorectomized women. Psychosom Med 1988;49:397.

    Article  Google Scholar 

  106. Guzman M, Saborido A, Castro J, Molano F, Megias A. Treatment with anabolic steroids increases the activity of the mitochondrial outer carnitine palmitoyltransferase in rat liver and fasttwitch muscle. Biochem Pharmacol 1991;41:833.

    Article  CAS  PubMed  Google Scholar 

  107. Krakower GR, Meier DA, Kissebah AH. Female sex hormones, perinatal, and peripubertal androgenization on hepatocyte insulin dynamics in rats. Am J Physiol 1993;264:E342.

    Article  CAS  PubMed  Google Scholar 

  108. Shima S. Effects of androgen treatment on adenylate cyclase system in rat hepatic membranes. Pharmacol Toxicol 1992;70:429.

    Article  CAS  PubMed  Google Scholar 

  109. Kyakumoto S, Sato N, Nemoto T, Ohara-Nemoto Y, Ota M. Binding of [3H]methyltrienolone to androgen receptor in rat liver. Biochim Biophys Acta 1984;800:214.

    Article  CAS  PubMed  Google Scholar 

  110. Bannister P, Randall VA, Sheridan P, Losowsky MS. Identification of the classical androgen receptor in male rat liver. J Recept Res 1986;6:73.

    Article  CAS  PubMed  Google Scholar 

  111. Eagon PK, Elm MS, Stafford EA, Porter LE. Androgen receptor in human liver: Characterization and quantitation in normal and diseased liver. Hepatology 1994;19:92.

    Article  CAS  PubMed  Google Scholar 

  112. Poretsky L, Bhargava G, Saketos M, Dunaif A. Regulation of human ovarian insulin receptors in vivo. Metabolism 1990;39:161.

    Article  CAS  PubMed  Google Scholar 

  113. Nestler JE, Powers LP, Matt DW, et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991;72:83.

    Article  CAS  PubMed  Google Scholar 

  114. Lee IR, Dawson SA, Wetherall JD, Hahnel R. Sex hormone-binding globulin secretion by human hepatocarcinoma cells is increased by both estrogens and androgens. J Clin Endocrinol Metab 1987;64:825.

    Article  CAS  PubMed  Google Scholar 

  115. Plymate SR, Matej LA, Jones RE, Friedl KE. Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metab 1988;67:460.

    Article  CAS  PubMed  Google Scholar 

  116. Marynick SP, Chakmakjian ZH, McCaffree DL, Herndon JH Jr. Androgen excess in cystic acne. N Engl J Med 1983;308:981.

    Article  CAS  PubMed  Google Scholar 

  117. Imperato-McGinley J, Gautier T, Cai LQ, Yee B, Epstein J, Pochi P. The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity. J Clin Endocrinol Metab 1993;76:524.

    CAS  PubMed  Google Scholar 

  118. Choudhry R, Hodgins MB, Van der Kwast T, Brink-mann AO, Boersma WJ. Localization of androgen receptors in human skin by immunohistochemistry: Implications for the hormonal regulation of hair growth, sebaceous glands and sweat glands. J Endocrinol 1992;133:467.

    Article  CAS  PubMed  Google Scholar 

  119. Randall VA, Thornton MJ, Messenger AG. Cultured dermal papilla cells from androgen-dependent human hair follicles (e.g. beard) contain more androgen receptors than those from non-balding areas of scalp. J Endocrinol 1992;133:141.

    Article  CAS  PubMed  Google Scholar 

  120. Randall VA, Thornton MJ, Messenger AG, Hibberts NA, Loudon AS, Brinklow BR. Hormones and hair growth: Variations in androgen receptor content of dermal papilla cells cultured from human and red deer (Cervus elaphus) hair follicles. J Invest Dermatol 1993;114:114S.

    Article  Google Scholar 

  121. Mowszowicz I, Riahi M, Wright F, Bouchard P, Kuttenn F, Mauvais JP. Androgen receptor in human skin cytosol. J Clin Endocrinol Metab 1981;52:338.

    Article  CAS  PubMed  Google Scholar 

  122. Mowszowicz I, Melanitou E, Doukani A, Wright F, Kuttenn F, Mauvais JP. Androgen binding capacity and 5 alpha-reductase activity in pubic skin fibroblasts from hirsute patients. J Clin Endocrinol Metab 1983;56:1209.

    Article  CAS  PubMed  Google Scholar 

  123. Kirschner MA. Hirsutism and virilism in women. Spec Top Endocrinol Metab 1984;6:55.

    CAS  PubMed  Google Scholar 

  124. Serafini P, Ablan F, Lobo RA. 5 Alpha-reductase activity in the genital skin of hirsute women. J Clin Endocrinol Metab 1985;60:349.

    Article  CAS  PubMed  Google Scholar 

  125. Biffignandi P, Massucchetti C, Molinatti GM. Female hirsutism: Pathophysiological considerations and therapeutic implications. Endocr Rev 1984;5:498.

    Article  CAS  PubMed  Google Scholar 

  126. Valentino R, Savastano S, Tommaselli AP, et al. Hormonal pattern in women affected by rheumatoid arthritis. J Endocrinol Invest 1993;16:619.

    Article  CAS  PubMed  Google Scholar 

  127. Lahita RG. The effects of sex hormones on the immune system in pregnancy. Am J Reprod Immunol 1992;28:136.

    Article  CAS  PubMed  Google Scholar 

  128. Fox HS. Androgen treatment prevents diabetes in nonobese diabetic mice. J Exp Med 1992;175:1409.

    Article  CAS  PubMed  Google Scholar 

  129. Grossman C, Roselle G, Mendenhall L. Sex steroid regulation of autoimmunity. J Steroid Biochem Mol Biol 1991;40:649.

    Article  CAS  PubMed  Google Scholar 

  130. Vojtiskova M, Polackova M, Viklicky V. Effect of an antiandrogen on the lymphoid system. Experientia 1976;32:1202.

    Article  CAS  PubMed  Google Scholar 

  131. Tindall DJ, Chang CH, Lobl TJ, Cunningham GR. Androgen antagonists in androgen target issues. Pharmacol Ther 1984;24:367.

    Article  CAS  PubMed  Google Scholar 

  132. Neumann F, Topert M. Pharmacology of antiandrogens. J Steroid Biochem 1986;25:885.

    Article  CAS  PubMed  Google Scholar 

  133. Lobl TJ, Campbell JA, Tindall DJ, Cunningham GR, Means AR. A model for the mechanism of androgen binding, transport, and translocation to the nucleus. In: Steinberger A, Steinberger E, eds. Testicular development, structure and function. New York: Raven Press, 1980:323.

    Google Scholar 

  134. Eil C, Edelson SK. The use of human skin fibroblasts to obtain potency estimates of drug binding to androgen receptors. J Clin Endocrinol Metab 1984;59:51.

    Article  CAS  PubMed  Google Scholar 

  135. Tindall D, French J, Nayfeh FS. Estradiol-17p inhibition of androgen uptake, metabolism and binding in epididymis of adult male rats in vivo: A comparison with cyproterone acetate. Steroids 1981;37:257.

    Article  CAS  PubMed  Google Scholar 

  136. Humpel M, Wendt H, Schulze P-E, Dogs G, Weiss C, Speck U. Bioavailability and pharmacokinetics of cyproterone acetate after oral administration of 2.0 mg cyproterone acetate in combination with 50 fxg ethinyloestradiol to 6 young women. Contraception 1977;15:579.

    Article  CAS  PubMed  Google Scholar 

  137. Mowszowicz I, Wright F, Vincens M, et al. Androgen metabolism in hirsute patients treated with cyproterone acetate. J Steroid Biochem 1984;20:757.

    Article  CAS  PubMed  Google Scholar 

  138. Ebling FJ, Randall VA. Steroid inhibitors of androgen-potentiated actions on skin. J Steroid Biochem 1983;19:587.

    Article  CAS  PubMed  Google Scholar 

  139. Garner PR, Poznanski N. Treatment of severe hirsutism resulting from hyperandrogenism with the reverse sequential cyproterone acetate regimen. J Reprod Med 1984;29:232.

    CAS  PubMed  Google Scholar 

  140. Golland IM, Elstein ME. Results of an open one-year study with Diane-35 in women with polycystic ovarian syndrome. Ann N Y Acad Sci 1993;687:263.

    Article  CAS  PubMed  Google Scholar 

  141. Kuttenn F, Rigaud C, Wright F, Mauvais-Jarvis P. Treatment of hirsutism by oral cyproterone acetate and percutaneous estradiol. J Clin Endocrinol Metab 1980;51:1107.

    Article  CAS  PubMed  Google Scholar 

  142. Hammerstein J, Meckies J, Leo-Rossberg I, Moltz L, Zielske F. Use of cyproterone acetate (CPA) in the treatment of acne, hirsutism, and virilism. J Steroid Biochem 1975;6:827.

    Article  CAS  PubMed  Google Scholar 

  143. Neumann F. Pharmacological basis for clinical use of antiandrogens. J Steroid Biochem 1983;19:391.

    Article  CAS  PubMed  Google Scholar 

  144. Greenwood R, Brummitt L, Burke B, Cunliffe WJ. Acne: Double blind clinical and laboratory trial of tetracycline, oestrogen-cyproterone acetate, and combined treatment. Br Med J (Clin Res Ed) 1985;291:1231.

    Article  CAS  Google Scholar 

  145. Eden JA. The polycystic ovary syndrome presenting as resistant acne successfully treated with cyproterone acetate. Med J Aust 1991;155:677.

    Article  CAS  PubMed  Google Scholar 

  146. Barth JH, Cherry CA, Wojnarowska F, Dawber RP. Cyproterone acetate for severe hirsutism: Results of a doubleblind doseranging study. Clin Endocrinol (Oxf) 1991;35:5.

    Article  CAS  Google Scholar 

  147. Lachnit FU. The development and evaluation of an ovulation inhibitor (DIAne) containing an antiandrogen. Acta Obstet Gynecol Scand Suppl 1979;88:33.

    Article  Google Scholar 

  148. Belisle S, Love EJ. Clinical efficacy and safety of cyproterone acetate in severe hirsutism: Results of a multicen-tered Canadian study. Fertil Steril 1986;46:1015.

    Article  CAS  PubMed  Google Scholar 

  149. Miller JA, Wojnarowska FT, Dowd PM, et al. Antiandrogen treatment in women with acne: A controlled trial. Br J Dermatol 1986;114:705.

    Article  CAS  PubMed  Google Scholar 

  150. Vermeulen A, Rubens R. Effects of cyproterone acetate plus ethinylestradiol low dose on plasma androgens and lipids in mildly hirsute or acneic young women. Contraception 1988;38:419.

    Article  CAS  PubMed  Google Scholar 

  151. Stivel MS, Kauli R, Kaufman H, Laron Z. Adrenocortical function in children with precocious sexual development during treatment with cyproterone acetate. Clin Endocrinol 1982;16:163.

    Article  CAS  Google Scholar 

  152. Cella J A, Tweit RC. Steroidal aldosterone blockers II. J Org Chem 1959;24:1109.

    Article  CAS  Google Scholar 

  153. Corvol P, Michaud A, Mevard A, Freifeld M, Mahoudeau J. Anti-androgenic effects of spironolactone. Endocrinology 1975;97:52.

    Article  CAS  PubMed  Google Scholar 

  154. Carter DB, Silverberg AB, Harris SE. Effect of spironolactone on androgen-dependent proteins in the ventral prostate of the rat. J Endocrinol 1980;86:471.

    Article  CAS  PubMed  Google Scholar 

  155. Schane HP, Potts GO. Oral progestational activity of spironolactone. J Clin Endocrinol Metab 1978;47:691.

    Article  CAS  PubMed  Google Scholar 

  156. Levy J, Burshell A, Marbach M, Afllalo L, Glick SM. Interaction of spironolactone with oestradiol receptors in cytosol. J Endocrinol 1980;84:371.

    Article  CAS  PubMed  Google Scholar 

  157. Namer M. Clinical applications of antiandrogens. J Steroid Biochem 1988;31:719.

    Article  CAS  PubMed  Google Scholar 

  158. Menard RH, Guenthner TM, Kon H, Gillette JR. Studies on the destruction of adrenal and testicular cytochrome P-450 by spironolactone. J Biol Chem 1979;254:1726.

    CAS  PubMed  Google Scholar 

  159. Serafini PC, Catalino J, Lobo RA. The effect of spironolactone on genital skin 5 alpha-reductase activity. Steroid Biochem 1985;23:191.

    Article  CAS  Google Scholar 

  160. Gardiner P, Schrode K, Quinlan D, et al. Spironolactone metabolism: Steady-state serum levels of the sulfur-containing metabolites. J Clin Pharmacol 1989;29:342.

    Article  CAS  PubMed  Google Scholar 

  161. Overdiek HW, Merkus FW. Influence of food on the bioavailability of spironolactone. Clin Pharmacol Ther 1986;40:531.

    Article  CAS  PubMed  Google Scholar 

  162. Karim A, Hribar J, Doherty M, et al. Spironolactone: Diversity in metabolic pathways. Xenobiotica 1977;7:585.

    Article  CAS  PubMed  Google Scholar 

  163. Karim A, Hribar J, Aksamit W, Doherty M, Chinn LJ. Spironolactone metabolism in man studied by gas chro-matography-mass spectrometry. Drug Metab Dispos 1975;3:467.

    CAS  PubMed  Google Scholar 

  164. Muraki T, Nakadate T, Kubota K, Tokunaga Y, Kato R. Effects of repeated administration of potassium canrenoate (SC-14266) on serum gonadotrophin, prolactin, testosterone and progesterone in male rats. Experientia 1980;36:668.

    Article  CAS  PubMed  Google Scholar 

  165. Shapiro G, Evron S. A novel use of spironolactone: Treatment of hirsutism. J Clin Endocrinol Metab 1980;51:429.

    Article  CAS  PubMed  Google Scholar 

  166. Gamborg NP. Treatment of idiopathic hirsutism with spironolactone. Dermatologica 1982;165:194.

    Article  Google Scholar 

  167. Ylostalo P, Heikkinen J, Kauppila A, Pakarinen A, Jarvinen PA. Low-dose spironolactone in the treatment of female hirsutism. Int J Fertil 1987;32:41.

    CAS  PubMed  Google Scholar 

  168. Milewicz A, Silber D, Kirschner MA. Therapeutic effects of spironolactone in polycystic ovary syndrome. Obstet Gynecol 1983;61:429.

    CAS  PubMed  Google Scholar 

  169. Dorrington WP, McCartney AC, Holland S, et al. The effect of spironolactone on hirsutism and female androgen metabolism. Clin Endocrinol (Oxf) 1985;23:161.

    Article  Google Scholar 

  170. Messina M, Manieri C, Biffignandi P, Massucchetti C, Novi RF, Molinatti GM. Antiandrogenic properties of spironolactone. Clinical trial in the management of female hirsutism. J Endocrinol Invest 1983;6:23.

    Article  CAS  PubMed  Google Scholar 

  171. Cumming DC, Yang JC, Rebar RW, Yen SS. Treatment of hirsutism with spironolactone. JAMA 1982;247:1295.

    Article  CAS  PubMed  Google Scholar 

  172. Ames RP, Hill P. Raised serum lipid concentrations during diuretic treatment of hypertension: A study of predictive indexes. Clin Sci Mol Med Suppl 1978;4:311S.

    CAS  PubMed  Google Scholar 

  173. Hughes BR, Cunliffe WJ. Tolerance of spironolactone. Br J Dermatol 1988;118:687.

    Article  CAS  PubMed  Google Scholar 

  174. Cusan L, Dupont A, Gomez J-L, Tremblay RR, Labrie F. Comparison of flutamide and spironolactone in the treatment of hirsutism: A randomized controlled trial. Fertil Steril 1994;61:281.

    Article  CAS  PubMed  Google Scholar 

  175. Tremblay RR. Treatment of hirsutism with spironolactone. Clin Endocrinol Metab 1986;15:363.

    Article  CAS  PubMed  Google Scholar 

  176. Biffignandi P, Molinatti GM. Antiandrogens and hirsutism. Horm Res 1987,28:242.

    Article  CAS  PubMed  Google Scholar 

  177. Nielsen PG. Treatment of female acne vulgaris with a cream containing the antiandrogen canrenone. Derma tologica 1983;166:275.

    Article  CAS  Google Scholar 

  178. Ojasoo T, Raynaud JP. Unique steroid congeners for receptor studies. Cancer Res 1978;38:4186.

    CAS  PubMed  Google Scholar 

  179. Schulz M, Schmoldt A, Donn F, Becker H. The pharmacokinetics of flutamide and its major metabolites after a single oral dose and during chronic treatment. Eur J Pharmacol 1988;34:633.

    CAS  Google Scholar 

  180. Kontula KK, Seppanen PJ, van Duyne P, Bardin CW, Janne OA. Effect of a nonsteroidal antiandrogen, flutamide, on androgen receptor dynamics and ornithine decarboxylase gene expression in mouse kidnev. Endocrinology 1985;116:226.

    Article  CAS  PubMed  Google Scholar 

  181. Kemppainen JA, Lane MV, Sar M, Wilson EM. Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. J Biol Chem 1992;267:968.

    CAS  PubMed  Google Scholar 

  182. Simard J, Luthy I, Guay J, Belanger A, Labrie F. Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues. Mol Cell Endocrinol 1986;44:261.

    Article  CAS  PubMed  Google Scholar 

  183. Brogden R, Chrisp P. Flutamide. Drugs Aging 1991;1:104.

    Article  CAS  PubMed  Google Scholar 

  184. Secreto G, Recchione C, Zambetti M, Fariselli G, Ballerini P. Hormonal changes induced by the pure antiandrogen flutamide in postmenopausal women with advanced breast cancer. Eur J Cancer Clin Oncol 1988;24:867.

    Article  CAS  PubMed  Google Scholar 

  185. Diamanti E, Kaklas N, Georgiadou E, Spina J, Rangou D, Chlouverakis C. The impact of a pure antiandrogen on gonadotropin and prolactin secretion in women with PCO. Second International Capri Conference 1992:106.

    Google Scholar 

  186. Diamanti E, Kaklas N, Spina J, Geordiadou E, Rangou D, Chlouverakis K. Intraovarian regulators and polycystic ovary syndrome. The effect of an androgen receptor blocker on gonadotropin release and androgen levels in PCO. Satellite symposium of the 9th International Congress of Endocrinology, 1992.

    Google Scholar 

  187. Balzano S, Cappa M, Migliari R, et al. The effect of flutamide on basal and ACTH-stimulated plasma levels of adrenal androgens in patients with advanced prostate cancer. J Endocrinol Invest 1988;11:693.

    Article  CAS  PubMed  Google Scholar 

  188. Sir-Petermann T, Rabenbauer B, Wildt L. The effect of flutamide on pulsatile gonadotropin secretion in hyperan-drogenic women. Hum Reprod 1993;8:1807.

    Article  CAS  PubMed  Google Scholar 

  189. Knuth U, Hano R, Nieschlag E. Effect of flutamide or cyproterone acetate on pituitary and testicular hormones in normal men. J Clin Endocrinol Metab 1984;59:963.

    Article  CAS  PubMed  Google Scholar 

  190. Chandrasekhar Y, Armstrong DT. Regulation of uterine progesterone receptors by the nonsteroidal anti-androgen hydroxyflutamide. Biol Reprod 1991;45:78.

    Article  CAS  PubMed  Google Scholar 

  191. Cusan L, Dupont A, Belanger A, Tremblay RR, Manhes G, Labrie F. Treatment of hirsutism with the pure antiandrogen flutamide. J Am Acad Dermatol 1990;23:462.

    Article  CAS  PubMed  Google Scholar 

  192. Wysowski DK, Freiman JP, Tourtelot JB, Horton ML. Fatal and nonfatal hepatotoxicity associated with flutamide. Ann Intern Med 1993;118:860.

    Article  CAS  PubMed  Google Scholar 

  193. Rosman AS, Frissora-Rodeo C, Marshal AT, Reiter BP. Cholestatic hepatitis following flutamide. Dig Dis Sci 1993;38:1756.

    Article  CAS  PubMed  Google Scholar 

  194. Creaven PJ, Pendyala L, Tremblay D. Pharmacokinetics and metabolism of nilutamide. Urology 1991;37(suppl 2):13.

    Article  CAS  PubMed  Google Scholar 

  195. Pfitzenmeyer P, Foucher P, Piard F, et al. Nilutamide pneumonitis: A report on eight patients. Thorax 1992;47:622.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  196. Harris MG, Coleman SG, Faulds D, Chrisp P. Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging 1993;3:9.

    Article  CAS  PubMed  Google Scholar 

  197. Brimblecombe RW, Duncan WA, Durant GJ, et al. Characterization and development of cimetidine as a histamine H2-receptor antagonist. Gastroenterology 1978;74:339.

    Article  CAS  PubMed  Google Scholar 

  198. Winters SJ, Banks JL, Loriaux DL. Cimetidine is an antiandrogen in the rat. Gastroenterology 1979;76:504.

    CAS  PubMed  Google Scholar 

  199. Vigersky RA, Mehlman I, Glass AR, Smith CE. Treatment of hirsute women with cimetidine. N Engl J Med 1980;303:1042.

    Article  CAS  PubMed  Google Scholar 

  200. Aram H. Treatment of female androgenetic alopecia with cimetidine. Int J Dermatol 1987;26:128.

    Article  CAS  PubMed  Google Scholar 

  201. Lissak A, Sorokin Y, Calderon I, Dirnfeld M, Lioz H, Abramovici H. Treatment of hirsutism with cimetidine: A prospective randomized controlled trial. Fertil Steril 1989;51:247.

    Article  CAS  PubMed  Google Scholar 

  202. Golditch IM, Price VH. Treatment of hirsutism with cimetidine. Obstet Gynecol 1990;75:911.

    CAS  PubMed  Google Scholar 

  203. Brimblecombe RW, Leslie GB, Walker TF. Toxicology of cimetidine. Hum Toxicol 1985;4:13.

    Article  CAS  PubMed  Google Scholar 

  204. McConnell JD, Wilson JD, George FW, Geller J, Pappas F, Stoner E. Finasteride, an inhibitor of 5a-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992;74:505.

    CAS  PubMed  Google Scholar 

  205. Group TM-FS One-year experience in the treatment of benign prostatic hyperplasia with finasteride. J Androl 1991;12:372.

    Google Scholar 

  206. Imperato MJ, Gautier T, Cai LQ, Yee B, Epstein J, Pochi P. The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity. J Clin Endocrinol Metab 1993;76:524.

    Google Scholar 

  207. Grino P, Stoner E. Finasteride for the treatment and control of benign prostatic hyperplasia: Summary of phase III controlled studies. The finasteride study group. Eur Urol 1994;25 (suppl 1):24.

    Article  PubMed  Google Scholar 

  208. Morris JJ, Hughes LR, Glen AT, Taylor PJ. Nonsteroidal antiandrogens. Design of novel compounds based on an infrared study of the dominant conformation and hydrogen-bonding properties of a series of anilide antiandrogens. J Med Chem 1991;34:447.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 1st Department of Internal Medicine, University of Athens, Laiko Hospital, 34 Areos Street, P. Faliro, Athens, 175-62, Greece

    Evanthia Diamanti-Kandarakis MD, George Tolis MD & Antoni J. Duleba MD

  2. Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, Connecticut, USA

    Evanthia Diamanti-Kandarakis MD, George Tolis MD & Antoni J. Duleba MD

Authors
  1. Evanthia Diamanti-Kandarakis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George Tolis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Antoni J. Duleba MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Diamanti-Kandarakis, E., Tolis, G. & Duleba, A.J. Androgens and Therapeutic Aspects of Antiandrogens in Women. Reprod. Sci. 2, 577–592 (1995). https://doi.org/10.1177/107155769500200401

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1177/107155769500200401

Key words

Search

Navigation